[Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
Selective alpha-1-adrenoblockers are thought promising in current conservative treatment of benign prostatic hyperplasia (BPH). The trial of doxazosin (cardura)--a selective alpha-blocker--included 78 BPH patients with obstructive urination. All the patients received a single daily dose of doxazosin 4-8 mg (mean 5.7 mg). 60 patients on placebo served as control. The comparison of the effects observed in the study vs control group has demonstrated that doxazosin has a favourable effect on BPH: it improved quality of life, relieved obstructive symptoms, reduced amount of residual urine. There is objective urodynamic evidence on decreased infravesical obstruction.
Lopatkin
N A
NA
Loran
O B
OB
Pushkar'
D Iu
DIu
Perepanova
T S
TS
Tevlin
K P
KP
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D017292:Doxazosin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D011788:Quality of Life; D014555:Urination Disorders / Q000188:drug therapy / Q000209:etiology
D000317:Adrenergic alpha-Antagonists; D017292:Doxazosin
Oøyt primeneniia doksazozina u bol'nykh dobrokachestvennoĭ giperplazieĭ prostaty.